Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Chronic lymphocytic leukemia (CLL) therapies often target kinase signaling.
• The PI3K/AKT pathway is crucial for cancer cell survival and proliferation.

Purpose of the Study:

• To investigate if hyperactivating the PI3K/AKT pathway can induce cell death in CLL.
• To explore the role of SH2-containing-inositol-5'-phosphatase-1 (SHIP1) in regulating this pathway in CLL.

Main Methods:

• Genetic manipulation to hyperactivate PI3K/AKT signaling.
• Inhibition of SHIP1 activity.
• Assessment of cell death, mitochondrial respiration, and reactive oxygen species (ROS) levels in CLL cells.

Main Results:

• Hyperactivation of PI3K/AKT signaling or SHIP1 inhibition led to acute cell death in CLL cells.
• SHIP1 inhibition increased AKT activity, mitochondrial respiration, and ROS accumulation.
• CLL cells possess mechanisms to balance PI3K/AKT activity to prevent ROS-induced death.

Conclusions:

• CLL cells rely on fine-tuning PI3K/AKT activity for survival and proliferation.
• Transient SHIP1 inhibition is a potential therapeutic strategy for CLL by inducing ROS-mediated cell death.